Opus Genetics, Inc. (IRD)
Nasdaq: IRD · Pharmaceutical Preparations · Durham, NC · filing with the SEC since 2003
Who owns Opus Genetics, Inc.
As filed with the SECHolders of 5% or more
6
Perceptive Advisors LLC holds 9.99% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13G/A filed Aug 14, 2026 says.
Directors and officers
15
report now, of 33 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 6 named at left.
Holders of 5% or moreshare of the class, as filed
Perceptive Advisors LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 9.99% in May 15, 2026
Adage Capital Management, L.P.
SCHEDULE 13G · filed May 13, 2026 · Common Stock, $0.0001 par value per share
Caligan Partners LP
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, $0.0001 par value per share · 8.5% in May 15, 2026
Balyasny Asset Management L.P.
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock · 7.18% in May 15, 2026
Nantahala Capital Management, LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 9.99% in Feb 13, 2026
Blackrock, Inc.
SCHEDULE 13G · filed Oct 27, 2026 · Common Stock
Foundation Fighting Blindness Retinal Degeneration Fund
SCHEDULE 13D/A · filed May 20, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 8% in Dec 11, 2025
Aaron G.L. Fletcher
SCHEDULE 13G/A · filed May 13, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.2% in Aug 11, 2025
What IRD reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Opus Genetics, Inc.
A company bought · acquisition · owns, named in the 10-K filed Mar 12, 2026
1 subsidiary in 1 country, from the list filed with the 10-K filed Mar 12, 2026.
Insider tradesForm 4
24sales
2purchases
1sales on a scheduled plan
7people selling
$19.7Msold, in dollars
$300,000bought, in dollars
Open-market trades on Form 4 from Nov 5, 2025 to Nov 5, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Nov 5, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window8 of 33 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Foundation Fighting Blindness Retinal Degeneration Fund | director | 3 | $18.8M | 0 | 0 | $0 |
| Magrath George | Chief Executive Officer | 5 | $300,000 | 0 | 0 | $0 |
| Yerxa Benjamin R | President | 4 | $200,000 | 0 | 0 | $0 |
| Gagnon Robert E. | Chief Financial Officer | 4 | $200,000 | 1 | 0 | $0 |
| Schachle Joseph K | Chief Operating Officer | 4 | $100,000 | 0 | 0 | $0 |
| Jayagopal Ashwath | Chief Scientific & Dev. Ofc. | 2 | $100,000 | 0 | 0 | $0 |
| Gallagher Cam | director | 0 | $0 | 0 | 2 | $300,000 |
| Zaremba Rabourn Amy | Head of Fin. Quality Assurance | 2 | $0 | 0 | 0 | $0 |